Compounds and methods for inhibiting hepatitis C virus replication
View Patent ↗The inventors have discovered that an ATPase-deficient dominant-negative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal structure of a multi-enzyme NS3 complex on a DNA substrate is also provided. The inventors have tested a peptide matching the sequence of a portion of NS3 that interacts with another NS3 molecule for inhibiting HCV replication. The peptide inhibits HCV replication. Accordingly, the invention provides a method of inhibiting HCV replication in cells infected with HCV involving transforming the cells with a vector expressing a dominant-negative mutant NS3 gene. The invention also provides a method of inhibiting HCV replication in cells infected with HCV involving administering to the cells a dominant-negative mutant NS3 protein. The invention also provides peptides and agents that inhibit HCV replication and methods of identifying agents that inhibit HCV replication.
1. A method of inhibiting hepatitis C virus (HCV) replication in cells infected with HCV comprising:
contacting the cells with an agent that inhibits NS3 enzyme activity by inhibiting NS3 oligomerization; wherein the agent reduces replication of viral nucleic acid in the cells or spread of virus to other cells;
wherein the agent is a vector expressing a dominant-negative mutant NS3 gene that expresses an ATPase-deficient NS3 protein that is 90% identical to SEQ ID NO:3 and the step of contacting the agent comprises transforming the cells with the vector;
wherein the ATPase-deficient NS3 protein comprises a D290A mutation; and
wherein the cells are in vitro.
2. A method of inhibiting hepatitis C virus (HCV) replication in cells infected with HCV comprising:
contacting the cells with an agent that inhibits NS3 enzyme activity by inhibiting NS3 oligomerization; wherein the agent reduces replication of viral nucleic acid in the cells or spread of virus to other cells;
wherein the agent is a peptide of 4 to 100 residues comprising at least 4 contiguous residues of HIDAHFLSQTK (SEQ ID NO:1) or at least 4 contiguous residues of reverse D sequence of SEQ ID NO:1.
3. The method of claim 2 wherein the agent comprises a peptide comprising the sequence HIDAHFLSQTK (SEQ ID NO:1).
4. The method of claim 3 wherein the agent is the peptide having the sequence HIDAHFLSQTKGGGYARAAARQARA (SEQ ID NO:2).
5. The method of claim 2 wherein the cells are in vitro.
6. The method of claim 2 wherein the agent is a peptide comprising the reverse D sequence of SEQ ID NO:1.